Skip to main content

9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one

ADVERTISEMENT
Identification
Molecular formula
C18H19N3O
CAS number
924660-85-1
IUPAC name
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
State
State

At room temperature, this compound is typically found as a solid. It is stable under standard conditions but should be stored in a dry and cool environment to maintain its integrity.

Melting point (Celsius)
218.00
Melting point (Kelvin)
491.15
Boiling point (Celsius)
378.50
Boiling point (Kelvin)
651.65
General information
Molecular weight
307.37g/mol
Molar mass
307.3680g/mol
Density
1.2430g/cm3
Appearence

This compound typically appears as a crystalline solid. It may vary in color but often is found in shades ranging from off-white to pale yellow, depending on purity and specific synthesis conditions.

Comment on solubility

Solubility of 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one

The solubility of the compound 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one (C18H19N3O) can be influenced by several factors.

Key Factors Affecting Solubility

  • Polarity: The presence of nitrogen (N) and oxygen (O) atoms often contributes to the overall polarity of a compound, affecting its ability to dissolve in polar solvents like water.
  • Hydrogen Bonding: Given the functional groups in this compound, the ability to form hydrogen bonds may increase its solubility in polar media.
  • Temperature: Generally, increasing the temperature can enhance solubility for many organic compounds, although exceptions exist.
  • pH Levels: The pH of the solvent can modify the ionization state of certain functional groups and thus alter solubility.

Specifically, for this compound, it is likely to exhibit moderate solubility in polar solvents while being less soluble in non-polar solvents due to its complex structure and the presence of hydrophilic groups. Understanding these solubility characteristics is crucial for applications in pharmaceuticals and material sciences, where the solubility can significantly dictate the behavior of the compound in various environments.

In summary, the solubility of C18H19N3O is a nuanced topic that depends significantly on its structural features and external conditions.

Interesting facts

Interesting Facts about 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one

The compound known as 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one is a fascinating example of modern organic chemistry. It boasts a diverse array of applications and unique structural characteristics that attract the attention of researchers. Here are some notable facts:

  • Biological Relevance: Compounds with imidazole rings, like this one, often show significant biological activity, making them valuable in pharmaceutical development.
  • Structure Complexity: The intricate structure includes a carbazole unit, which is known for its photophysical properties and is a common motif in the study of organic semiconductors.
  • Synthesis Potential: Understanding the synthesis pathways of such compounds is vital for chemists, especially in optimizing reaction conditions for better yields.
  • Research Interest: As an area of active study, compounds of this nature can lead to new findings in medicinal chemistry, particularly in anti-cancer and anti-inflammatory research.
  • Interdisciplinary Approach: The study of this compound encourages a collaborative approach as it combines elements of synthetic chemistry, pharmacology, and material science.

  • Quote from a Chemist: As one renowned researcher stated, "The beauty of organic synthesis lies not only in the compounds we create but in the new possibilities they unveil in medicine and technology."

Researching 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one continues to inspire many in the field and promises potential breakthroughs that could impact various industries!

Synonyms
ondansetron
99614-02-5
Zofran
Zofran ODT
Zudan
9-Methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-2,3-dihydro-1H-carbazol-4(9H)-one
Zuplenz
116002-70-1
Ondansetron Injection
GR 38032X
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
GR 38032
UNII-4AF302ESOS
4AF302ESOS
BRN 3622981
DTXSID8023393
A04AA01
EUR-1025
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one
NSC-757870
99614-01-4
Ondansetron [USP:INN:BAN]
1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one
CHEBI:7773
DTXCID803393
HSDB 8304
NSC 757870
NCGC00179341-02
GR-38032F/GR-38032
Odansetron [common misspelling of ondansetron]
1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one
ONDANSETRON (MART.)
ONDANSETRON [MART.]
ONDANSETRON (USP-RS)
ONDANSETRON [USP-RS]
Ondansetron (USP:INN:BAN)
GR 38032 (hydrochloride);SN 307 (hydrochloride)
ondansetron (Zofran)
Ondansetron, (+,-)-Isomer
ONDANSETRON (USP MONOGRAPH)
ONDANSETRON [USP MONOGRAPH]
(+/-)-2,3-DIHYDRO-9-METHYL-3-((2-METHYLIMIDAZOL-1-YL)METHYL)CARBAZOL-4(1H)-ONE
9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-1,2,3,9-tetrahydro-4H-carbazol-4-one
CAS-99614-02-5
Zofran ODT (TN)
Odansetron (common misspelling of ondansetron)
DESMETHYLONDANSETRON
ondansetronum
ondasetron
Ondansetron (JAN/USP/INN)
OndansetronODT
SR-01000763250
MFCD00833882
Ondansetron (Standard)
CHEMBL46
ONDANSETRON [MI]
Prestwick0_001058
Prestwick1_001058
Prestwick2_001058
Prestwick3_001058
ONDANSETRON [INN]
ONDANSETRON [JAN]
ONDANSETRON [VANDF]
SCHEMBL4542
TimTec1_001750
(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one
4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-
Oprea1_435466
Oprea1_852372
BSPBio_001016
CBDivE_008994
ONDANSETRON [WHO-DD]
MLS006011928
SPBio_002938
BPBio1_001118
GTPL2290
HY-B0002BR
BDBM85330
HY-B0002B
ONDANSETRON [ORANGE BOOK]
(3S)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
HMS2090H16
HMS3259H08
HMS3371E18
BCP28911
Tox21_113048
CAS_68647
NSC_68647
NSC791005
s1996
STK370548
AKOS000599484
AKOS016340526
Tox21_113048_1
BCP9001025
DB00904
GR38032
KS-5227
NC00706
NSC-791005
1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H- carbazol-4-one
NCGC00179341-04
NCGC00179341-07
NCGC00179341-12
AC-28927
FO157236
GR-38032
NCI60_022780
SMR001307702
Ondansetron(base and/or unspecified salts)
GR 38032F;GR-C507/75
AB00373674
NS00010141
C07325
D00456
EN300-117273
AB00373674-15
AB00373674-17
AB00373674_18
AB00373674_19
L000456
Q410011
SR-01000763250-4
BRD-A19736161-001-01-8
BRD-A19736161-001-05-9
BRD-A19736161-001-06-7
BRD-A19736161-003-03-0
BRD-A19736161-003-14-7
Z1501485364
2,3-Dihydro-9-methyl-3-((2-methylimidazol-1-yl)methyl)carbazol-4(1H)-one
1,2,3,4-Tetrahydro-9-methyl-3-(2-methyl-1H-imidazol-1-ylmethyl)carbazole-4-one
1,2,3,9,-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one
1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1yl)methyl]-4H-carbazol-4-one
1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1 -yl)methyl]-4H-carbazol-4-one
1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1-yl)methyl]-4H-carbazol-4-one
4H-Carbazol-4-one,?1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-
9-Methyl-3- (2-methyl-imidazol-1ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1~{H}-carbazol-4-one
4H-CARBAZOL-4-ONE, 1,2,3,9-TETRAHYDRO-9-METHYL-3-((2-METHYL-1H-IMIDAZOL-1-YL)METHYL)- (+/-)-
4H-CARBAZOL-4-ONE, 1,2,3,9-TETRAHYDRO-9-METHYL-3-((2-METHYL-1H-IMIDAZOL-1-YL)METHYL)-(+/-)-